Cipla Ltd.

Cipla’s arm InvaGen Pharmaceuticals Inc is recalling 11 lots of antidepressant bupropion HCl extended-release tablets from the US market due to failed dissolution specifications. InvaGen Pharmaceuticals Inc is recalling four lots of bupropion HCl extended-release tablets USP (SR) in the strength of 100 mg. The company is also recalling seven lots of the tablets in the strength of 150 mg.

The ongoing nationwide voluntary recall for both the strengths is on account of failed dissolution specifications; during stability testing. The recalls are a class III recall.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.